Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
gene editing
4
×
life sciences
national blog main
national top stories
4
×
san francisco blog main
san francisco top stories
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
ceo
clinical study
commissioner
crispr-cas9
detroit blog main
detroit top stories
editas medicine
enzyme
fda
genome editing
ipo
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
scott gottlieb
seattle blog main
seattle top stories
shutdown
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
ac immune
acquisition
What
medicine
4
×
bio
cas
crispr
editas
editing
gene
roundup
therapeutics
beam
benefit
big
biopharma
bosley's
bosley’s
bridge
bucks
car
celgene
ceo
colleagues
crime
departure
editor
exit
exome
founders
going
gotten
government
guiding
harvard
health
humans
hundreds
industry
isn't
jump
katrine
landmark
Language
Current search:
medicine
×
" national top stories "
×
" gene editing "
×
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M
